Research Projects All Projects
Projects

Quick links

Interaction and dynamics of intestinal IgA and gut microbiome profile during antidiabetic therapy

Project Title: „ Interaction and dynamics of intestinal IgA and gut microbiome profile during antidiabetic therapy”

Funding: European Regional Development Fund (ERDF), Measure 1.1.1.1 “Support for applied research”

Project No.: 1.1.1.1/19/A/036

Period: 1 May 2020 – 30 April 2023

Project costs: 648 648 EUR

Principle Investigator: Dr. biol. Jānis Kloviņš

Cooperation partner: SIA Latvia MGI Tech 

 

Project summary:

Type 2 diabetes (T2D) is a chronic disease affecting approximately 60 million people in the European Region that constitutes nearly 8.8% of the adult population. Despite its variable therapeutic effects, contraindications, and side effects, metformin is still the most frequently administered antidiabetic medication.  It has recently become clear that metformin alters gut microbiota composition and may exert its function through these alterations, while mechanisms underlying this interaction are not fully understood. In our previous research, we have found that secretory immunoglobulin A (sIgA) may be involved in mediating this interaction. Therefore, we propose a hypothesis that sIgA is an important mediator of metformin effects on the gut microbiome and significantly modulates the T2D treatment.

The overall aim of the project is to understand the modulatory effect of sIgA on gut microbiome specifically in case of T2D and the role of metformin in this process by using clinical investigation in humans and corresponding T2D mouse model in order to identify reliable omics-based biomarkers for predicting the treatment outcome and to identify new treatment strategies.

We are planning to implement human studies to research this phenomenon using excellent clinical resource including ongoing OPTIMED trial and Genome Database of Latvian Population (LGDB), as well as mice studies. We will employ state of the art technologies including massive parallel sequencing based metagenome and transcriptome analysis as well as metabolite analysis of sorted microbiome components in conjunction with rich clinical information.  The project will result in understanding not only the correlative associations between sIgA, microbiome, and T2D treatment efficacy but also functional mechanisms and causal interactions. 

Information published 05.05.2020.

 

Progress of the project:

1 May 2020 – 31 July 2020

Involvement of patients with type 2 diabetes and healthy controls in the study and collection of necessary samples for further analysis of the intestinal microbiome are underway. The optimization of the bacterial cell sorting method after sIgA binding has been started.

Information published 31.07.2020. 

 

Progress of the project:

1 August 2020 – 31 October 2020

The inclusion of patients with type 2 diabetes and healthy controls in the study and the collection of the necessary biological samples for further analysis of the intestinal microbiome are being continued. Optimization of bacterial cell sorting method after sIgA binding is performed, as well as preparation of biological samples for the functional analysis.

Information published 30.10.2020. 



Mājas lapas izstrādi finansēja ERAF 2.1.1.2. aktivitātes projekts Nr. 2010/0196/2DP/2.1.1.2.0/10/APIA/VIAA/004 "Latvijas biomedicīnas pētījumu integrācija Eiropas zinātnes telpā".